Adam S. Cheifetz MD

Adam S. Cheifetz, MD, is a Professor of Medicine at Harvard Medical School and Director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center in Boston, Massachusetts.

Dr. Cheifetz received his medical degree from Cornell University Medical College in New York, New York. He then completed his internship and residency in internal medicine at Yale-New Haven Hospital in New Haven, Connecticut. Afterward, he completed two separate fellowships in clinical immunology and inflammatory bowel disease at Mount Sinai School of Medicine in New York, New York, as well as a fellowship in gastroenterology at Yale University School of Medicine.

He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases (IBD). He is involved in multiple research projects relating to IBD and has published over 200 articles and chapters on the subject. His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.